Maxim Group analyst Michael Okunewitch downgrades $Gilead Sciences (GILD.US)$ to a hold rating.
According to TipRanks data, the analyst has a success rate of 34.0% and a total average return of -14.6% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Gilead Sciences (GILD.US)$'s main analysts recently are as follows:
Gilead's recent financial results exceeded sales expectations, bolstered by robust performance within its HIV product lineup and higher than anticipated revenues from Veklury. The company's HIV segment experienced a solid quarter marked by ongoing volume increases and a positive product mix.
The company's third-quarter performance surpassed expectations, bolstered not only by Veklury but by Biktarvy as well.
The sentiment is that significant changes are underway for the company, as it shifts away from past business development decisions and refocuses on its core strength in antiviral innovation. The introduction of lenacapavir is anticipated to have a dual role, acting as a next-generation foundation for HIV treatment and potentially broadening the scope of PrEP to a wider audience. There's a belief that the PrEP market holds potential for expansion beyond the traditional high-risk demographics. In the oncology space, there's notable progress, with TRODELVY experiencing double-digit growth and a promising partnership that could lead to a leading CAR-T therapy for multiple myeloma.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
Maxim Group分析师Michael Okunewitch下调$吉利德科学 (GILD.US)$至持有评级。
根据TipRanks数据显示，该分析师近一年总胜率为34.0%，总平均回报率为-14.6%。
此外，综合报道，$吉利德科学 (GILD.US)$近期主要分析师观点如下：
吉利德最近的财务业绩超出了销售预期，这得益于其HIV产品阵容的强劲表现以及Veklury高于预期的收入。该公司的HIV板块经历了稳健的季度业绩，其特点是销量持续增长，产品组合良好。
该公司第三季度的业绩超出了预期，这不仅得到了Veklury的支持，也得到了Biktarvy的推动。
人们认为，随着公司摆脱过去的业务发展决策，将重点重新放在抗病毒创新方面的核心优势上，该公司正在发生重大变化。预计来那卡韦的推出将起到双重作用，既是HIV治疗的下一代基础，又有可能将PrEP的范围扩大到更广泛的受众。人们认为，PrEP市场具有超越传统高风险人群的扩张潜力。在肿瘤学领域，取得了显著进展，TRODELVY实现了两位数的增长，合作前景光明，这可能会导致领先的多发性骨髓瘤CAR-T疗法。
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
